For approval of Unaudited Financial Results for quarter and nine months ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Standalone revenue collapsed sharply to Rs. 2.11 lakhs in Q3 FY26 from Rs. 88.33 lakhs in Q3 FY25, and 9M FY26 total income fell to Rs. 10.36 lakhs vs Rs. 147.26 lakhs in 9M FY25 — a drop of roughly 93%. Standalone net loss widened to Rs. 51.11 lakhs (9M FY26) from Rs. 15.45 lakhs (9M FY25); consolidated 9M loss was Rs. 93.62 lakhs. The company's own notes disclose that current liabilities exceed net realisable current assets by Rs. 3,685.58 lakhs (standalone), yet results are prepared on a Going Concern basis citing promoter/associate support, an MOU with Dismutase Biotech for a blood plasma protein project, and planned inorganic growth. Two step-down windfarm subsidiaries (30MW and 50MW) are being wound up. The auditor (R. Sundararajan & Associates) issued an unqualified limited review report.
This is a high-risk disclosure for shareholders — near-total revenue erosion and deepening losses, combined with a self-flagged going concern situation, signal serious business stress. Any near-term stock reaction will depend on credibility of the proposed biotech venture and M&A pipeline; investors should treat this as a cautionary deep-dive trigger rather than a clean results update.